Cargando…
Rituximab in refractory myasthenia gravis: a prospective, open‐label study with long‐term follow‐up
We examined the clinical effectiveness of rituximab in fourteen patients with refractory myasthenia gravis (MG). Manual muscle testing (MMT) score was recorded at baseline and followed during the course of the study. Steroid dose, frequency of intravenous immunoglobulin (IVIG) infusions, and plasma...
Autores principales: | Anderson, Dustin, Phan, Cecile, Johnston, Wendy S., Siddiqi, Zaeem A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931720/ https://www.ncbi.nlm.nih.gov/pubmed/27386504 http://dx.doi.org/10.1002/acn3.314 |
Ejemplares similares
-
Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial
por: Putko, Brendan N., et al.
Publicado: (2020) -
Refractory myasthenia gravis – clinical profile, comorbidities and response to rituximab
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2016) -
Rituximab treatment in myasthenia gravis
por: Vesperinas-Castro, Ana, et al.
Publicado: (2023) -
Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar
por: Fatehi, Farzad, et al.
Publicado: (2021) -
Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)